In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates

Molecular Immunology

Volumn 44, Issue 8, 2007, Pages 1903-1913

  Di Giambattista, Mario ^a   Branckaert, Theo ^a   Hougardy, Vincent ^a   Kemball Cook, Geoffrey ^b   Laub, Ruth ^a  

^a Rode Kruis Vlaanderen   (Belgium)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Continuous epitope; Human antibodies; In silico FVIII; Inhibitors; Intravenous immunoglobulins; Synthetic peptide

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; EPITOPE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; BLOOD CLOTTING INHIBITOR; F8 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ALGORITHM; ARTICLE; B LYMPHOCYTE; COMPUTER MODEL; EPITOPE MAPPING; METHODOLOGY; MOLECULAR CLONING; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; RABBIT; ANIMAL; AUTOIMMUNE DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; HEMOPHILIA A; HUMAN; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE;

ORYCTOLAGUS CUNICULUS;

ALGORITHMS; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BLOOD COAGULATION FACTOR INHIBITORS; EPITOPE MAPPING; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RABBITS;

EID: 33751529000     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.09.034     Document Type: Article

References (45)

1. Avrameas S., Taudou B., and Chuilon S. Glutaraldehyde, cyanuric chloride and tetrazotized O-dianisidine as coupling reagents in the passive hemagglutination test. Immunochemistry 6 (1969) 67-76
2. Di Giambattista M., Branckaert T., and Laub R. Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides. Biologicals 29 (2001) 229-232
3. Donath M.J.S.H., Lenting P.J., Van Mourik J.A., and Mertens K. Kinetics of factor VIII light-chain cleavage by thrombin and factor Xa: a regulatory role of the factor VIII heavy-chain region Lys713-Arg740. Eur. J. Biochem. 240 (1996) 365-372
4. Fay P.J., Haidaris P.J., and Smudzin T.M. Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J. Biol. Chem. 266 (1991) 8957-8962
5. Gilbert G.E., Kaufman R.J., Arena A.A., et al. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J. Biol. Chem. 277 (2002) 6374-6381
6. Giles R.A., Verbruggen B., Rivard G.E., et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detection factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb. Haemost. 79 (1998) 872-875
7. Gilles J.G., Peerlinck K., Arnout J., et al. Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors. Thromb. Haemost. 77 (1997) 938-943
8. Goudemand J., Rothschild C., Demiguel V., et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107 (2006) 46-51
9. Hu G.L., Okita D.K., and Conti-Fine B.M. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. J. Thromb. Haemost. 2 (2004) 1908-1917
10. Huang Y.W., Saidi P., and Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Haemophilia 10 (2004) 713-721
11. Jacquemin M., De Maeyer M., D'Oiron R., et al. Molecular mechanisms of mild and moderate hemophilia A. J. Thromb. Haemost. 1 (2003) 2722
12. Jacquemin M., Lavend'homme R., Benhida A., et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 96 (2000) 958-965
13. Lapan K.A., and Fay P.J. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb. Haemost. 80 (1998) 418-422
14. Laub R., Di Giambattista M., Fondu P., et al. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb. Haemost. 81 (1999) 39-44
15. Lemieux R., and Bazin R. Autoantibody-induced formation of immune complexes in normal human serum. Curr. Pharm. Des. 12 (2006) 173-179
16. 1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J. Biol. Chem. 271 (1996) 1935-1940
17. Liles D.K., Monroe D.M., and Roberts H.R. The factor VIII peptide consisting of amino acids 698 to 712 enhances factor IXa cleavage of factor X. Blood 90 Suppl. 1 (1997) 463a
18. Liu F.T., Zinnecker M., Hamaoka T., and Katz D.H. New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. Biochemistry 18 (1979) 690-693
19. Liu M.L., Shen B.W., Nakaya S., et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 96 (2000) 979-987
20. Lollar P. Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematology 85 Suppl. 10 (2000) 26-30
21. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J. Thromb. Haemost. 2 (2004) 1082-1095
22. Lubahn B.C., Ware J., Stafford D.W., and Reisner H.M. Identification of a F. VIII epitope recognized by a human hemophilic inhibitor. Blood 73 (1989) 497-499
23. Moreau A., Lacroix-Desmazes S., Stieltjes N., et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 95 (2000) 3435-3441
24. Nogami K., Freast J., Manithody C., et al. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J. Biol. Chem. 279 (2004) 33104-33113
25. Oldenburg J., Schröder J., Brackmann H.H., et al. Environmental and genetic factors influencing inhibitor development. Semin. Hematol. 41 Suppl. 1 (2004) 82-88
26. Parker J.M.R., Guo D., and Hodges R.S. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 25 (1986) 5425-5432
27. Parker J.M.R., and Hodges R.S. Prediction of surface and interior regions in proteins. Part I. linear tripeptide sequences identify structural boundaries in proteins. Peptide Res. 4 (1991) 347-354
28. Parker J.M.R., and Hodges R.S. Prediction of surface and interior regions in proteins. Part II: predicting secondary structure in regions bound by surface exposed regions. Peptide Res. 4 (1991) 355-363
29. Peerlinck K., Arnout J., Di Giambattista M., et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb. Haemost. 77 (1997) 80-86
30. Pratt K.P., Qian J., Ellaban E., et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb. Haemost. 92 (2004) 522-528
31. Pratt K.P., Shen B.W., Takeshima K., et al. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature 402 (1999) 439-442
32. Raut S., Di Giambattista M., Bevan S.A., et al. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb. Haemost. 80 (1998) 624-631
33. Reding M.T., Okita D.K., Diethelm-Okita B.M., et al. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. J. Thromb. Haemost. 2 (2004) 1385-1394
34. Reding M.T., Okita D.K., Diethelm-Okita B.M., et al. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J. Thromb. Haemost. 1 (2003) 1777-1784
35. Scandella D., Gilbert G.E., Shima M., et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86 (1995) 1811-1819
36. Schwartz R.S., Gabriel D.A., Aledort L.M., et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 86 (1995) 797-804
37. Shima M., Fulcher C.A., de Graaf Mahoney S., et al. Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp1663-Ser1669. J. Biol. Chem. 263 (1988) 10198-10203
38. Spiegle P.C., Jacquemin M., Saint-Remy J.M.R., et al. Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 98 (2001) 13-19
39. Stoilova-McPhie S., Villoutreix B.O., Mertens K., Kemball-Cook G., and Holzenburg A. 3-dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 99 (2002) 1215-1223
40. Tamura T., and Bauer H. Monoclonal antibody against the carboxy terminal peptide pp60src of Rous sarcoma virus reacts with native pp60src. Embo J. 1 (1982) 1479-1485
41. Van den Brink E.N., Turenhout E.A.M., Bank C.M.C., et al. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood 96 (2000) 540-545
42. Vehar G.A., Keyt B., Eaton D., et al. Structure of human factor VIII. Nature 312 (1984) 337-342
43. Wakabayashi H., Freas J., Zhou Q., and Fay P.J. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for Cofactor activity. J. Biol. Chem. 279 (2004) 12677-12684
44. Ware J., Toomey J.R., and Stafford D.W. Localization of anti-factor VIII monoclonal antibodies determined by recombinant peptides. Thromb. Haemost. 61 (1989) 225-229
45. Zhong D., Saenko E.L., Shima M., et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 92 (1998) 136-142